Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that the HbA1c reduction with fixed dose combination therapy of vildagliptin and metformin (25/1000 mg bid) is superior to that with metformin monotherapy (1000 mg bid) after 24 weeks of treatment in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy.
Critère d'inclusion
- Type II Diabetes